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AbstrACt
background In 2012, a European initiative called 
Single Hub and Access point for pediatric rheumatology 
in Europe (SHArE) was launched to optimise and 
disseminate diagnostic and management regimens in 
Europe for children and young adults with rheumatic 
diseases. Juvenile idiopathic arthritis (JIA) is the 
most common rheumatic disease in children and 
uveitis is possibly its most devastating extra-articular 
manifestation. Evidence-based guidelines are sparse and 
management is mostly based on physicians’ experience. 
Consequently, treatment practices differ widely, within 
and between nations.
Objectives to provide recommendations for the 
diagnosis and treatment of JIA-associated uveitis.
Methods recommendations were developed by 
an evidence-informed consensus process using the 
European League Against rheumatism standard 
operating procedures. A committee was constituted, 
consisting of nine experienced paediatric rheumatologists 
and three experts in ophthalmology from Europe. 
recommendations derived from a validated systematic 
literature review were evaluated by an Expert Committee 
and subsequently discussed at two consensus meetings 
using nominal group techniques. recommendations were 
accepted if >80% agreement was reached (including all 
three ophthalmologists).
results In total, 22 recommendations were accepted 
(with >80% agreement among experts): 3 on diagnosis, 
5 on disease activity measurements, 12 on treatment and 
2 on future recommendations.
Conclusions the SHArE initiative aims to identify best 
practices for treatment of patients suffering from JIA-
associated uveitis. Within this remit, recommendations 
for the diagnosis and treatment of JIA-associated 
uveitis have been formulated by an evidence-informed 
consensus process to suggest a standard of care for JIA-
associated uveitis patients throughout Europe.
IntrOduCtIOn
In 2012, Single Hub and Access point for pediatric 
Rheumatology in Europe (SHARE) was launched 
with the aim of optimising and disseminating diag-
nostic and management regimens for children and 
adolescents with rheumatic diseases. The European 
League against Rheumatism (EULAR) has produced 
a number of recommendations in the area of paedi-
atric rheumatology such as juvenile dermatomyositis1 
using a standardised procedure2 and referring to a 
generalised instrument for guideline assessment: the 
Appraisal of Guidelines for Research & Evaluation.3
Juvenile idiopathic arthritis (JIA) is the most 
common rheumatic disease in children, and uveitis 
is the most frequent and potentially most devastating 
extra-articular manifestation. There are no interna-
tional consensus statements specifically relating to 
the diagnosis and treatment of JIA-associated uveitis 
although there are national guidelines from Germany 
and Spain.4 5 Management is therefore based on physi-
cians’ personal experience; and considerable variation 
in clinical practice, both in terms of investigation and 
management of JIA-associated uveitis, was found in an 
extensive survey of uveitis experts.6
With the rapid development of novel therapies 
for JIA, clear recommendations based on avail-
able best evidence and expert opinion (when trial 
evidence is lacking) will help physicians in the care 
of patients with JIA-associated uveitis. The uveitis 
seen with JIA is usually chronic anterior uveitis 
which is asymptomatic, but acute anterior uveitis 
can also be seen in the enthesitis-related arthritis 
subtype.7 8 There is a clear need to regularly update 
those managing patients with JIA uveitis through 
expert opinion. While the majority of treatments 
available for the treatment of arthritis have a solid 
evidence base from clinical trials, corresponding 
data for patients with uveitis may not be known or 
the level of evidence may not be as strong at the 
time of their introduction into clinical practice.
The primary aims of the recommendations 
forwarded by the Expert Group were to develop 
agreed strategies to
 ► prevent or reduce the likelihood of JIA-associ-
ated uveitis from occurring and minimise the 
damage at the time of diagnosis
 ► recommend treatments and management 
strategies that would reduce inflammation 
and prevent the development of those ocular 
complications most likely to cause irreversible 
visual loss.
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Figure 1 Summary of search strategy for identification of key articles.
MetHOds
A committee of 12 experts (AH, BV, CP, CE, SC-G, IF, JdB, 
JA, KW, RG, YU, NW) in paediatric rheumatology (n=9) or 
ophthalmology (n=3) was established to develop recommenda-
tions for JIA-associated uveitis based on consensus, but evidence 
informed, using EULAR standard operating procedures for 
developing best practice.2 3
systematic literature search
The electronic databases PubMed/MEDLINE, Embase and 
Cochrane were searched independently by two researchers for 
eligible articles in February 2015. All synonyms of JIA were 
searched in Medical Subject Headings/Emtree terms, titles 
and abstracts (figure 1). Reference tracking was performed in 
all included studies (full search strategy is shown in figure 1). 
Experts (TC, AP, VB) selected papers relevant to uveitis asso-
ciated with JIA investigations and/or treatment to be taken 
forward for validity assessment (inclusion and exclusion criteria 
shown in figure 1) by members of the expert committee.
Validity assessment
The selected articles were randomly allocated to the expert 
group, and two members per paper independently assessed the 
methodological quality of those papers meeting the inclusion 
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table 1 Recommendations for diagnosis and screening in juvenile idiopathic arthritis (JIA)-related uveitis
recommendation L  s Agreement (%) references
1. All patients in whom a diagnosis of JIA is being considered should be screened for uveitis according to a 
contemporary and audited protocol. Formal screening protocol should be administered in all centres, where patients 
with JIA are seen.
2A B 100 13–32
2. Frequency of ophthalmological follow-up visits must be based on disease severity and needs to be decided in 
conjunction with an expert ophthalmologist.
4 D 100 13–27 33–66
3. Patients with JIA stopping any systemic immunosuppressant are at risk of developing new onset uveitis or 
recurrence of uveitis after a prolonged remission. After stopping systemic immunosuppression, it is recommended 
that all patients with JIA are screened by an ophthalmologist at least every three months for at least 1 year. 
2B B 100 67–70
Agreement indicates the % of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, cohort studies; 2B, case–control studies; 3, non-comparative descriptive studies; 4, expert 
opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated 
from level 3 or 4 expert opinion. L, level of evidence; S, strength of evidence.
table 2 Recommendations for disease activity measurement in juvenile idiopathic arthritis (JIA)-related uveitis
L s Agreement (%) references
4. There should be good communication between the ophthalmologist and the paediatric rheumatologist 
concerning changes in disease activity treatment changes and responsibility for treatment monitoring.
3 C 100 71
5. There is a need to develop shared outcome measures to help guide decisions on systemic treatment. 4 D 100
6. At present, there is no validated biomarker to follow the activity of uveitis. 2A B 100 4 21 29 31 32 37 41 46 72–76
7. At present, no widely accepted definition of inactive disease for JIA-related uveitis is available. The goal 
of treating JIA-associated uveitis should be no cells in the anterior chamber. The presence of macular and/
or disk oedema, ocular hypotony and rubeosis iridis may require anti-inflammatory treatment even in the 
absence of AC cells.
2B B 100 4 69 78
8. We recommend 2 years of inactive disease off topical steroids before reducing systemic 
immunosuppression (both DMARDs and biological therapies).
3 C 92 67
Agreement indicates the % of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, cohort studies; 2B, case–control studies; 3, non-comparative descriptive studies; 4, expert 
opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated 
from level 3 or 4 expert opinion. DMARD, disease-modifying anti rheumatic drugs; L, level of evidence; S, strength of evidence.
criteria (figure 1). Data were extracted using predefined scoring 
forms for diagnostic and therapeutic studies. Disagreements 
were resolved by discussion or by the opinion of a third expert. 
Adapted classification tables for diagnostic, therapeutic and 
epidemiological studies were used to determine the level of 
evidence and strength of each recommendation.9–11
establishment of recommendations
As part of the EULAR standard operating procedure, experts 
described the main results and conclusions of each paper, along 
with their validity and level of evidence. These descriptions 
were collated by five experts (TC, GS, YU, RG, JdB) and used 
to formulate provisional recommendations which were reviewed 
by a panel of three experts (IF, NW, JdB). A summary of the 
evidence was presented along with each provisional recommen-
dation to the expert committee. The recommendations were 
revised and discussed at a face-to-face meeting in March 2014 
(Genova: 12 participants), using a Nominal Group Technique 
to reach a consensus.12 A non-voting expert (AR) facilitated the 
process. Recommendations were accepted when ≥80% (10 of 
12) of the experts agreed (including all three ophthalmologists).
resuLts
Literature review
The literature search yielded a total of 1323 papers which, after 
deduplication, left 1259 unique articles. Evaluation of inclusion/
exclusion criteria in titles and/or abstracts resulted in a core 
reference database of 176 articles for which full-text copies 
were obtained for quality screening by the expert committee. Of 
these, 117 were selected to support the development of consen-
sus-based recommendations by the expert group (figure 1).
recommendations
The sections that follow report the recommendations of the expert 
committee based on the supporting literature.13–128 Tables 1–4 
summarise the recommendations, the level of evidence that 
they provide and the strength of the recommendation, and the 
percentage of experts who agreed with these assessments.
background
JIA is the most common chronic rheumatic disease in children 
with an incidence of 8.2 (7.5–9.0)/100 000 of the population 
under 16 and an annual prevalence of approximately 70.2 [16 
– 140]/100 000.129 130 The wide prevalence range has been 
attributed to the different study designs employed, but the inci-
dence is thought to vary little worldwide.130 The incidence of 
JIA-associated uveitis is thought to be approximately 1/10 000 
and there is some evidence that it is less frequent in oriental 
populations with JIA.7 131
Structural complications, some of them leading to irrevers-
ible visual loss, include cataracts, glaucoma, band keratopathy, 
macular oedema, retinal detachment and sequelae associated 
with chronic hypotony. The uveitis usually has an insidious time 
course and can be chronic or recurrent but, most frequently, 
JIA-associated uveitis is a chronic relapsing condition lasting 
several years. It almost universally starts as an anterior uveitis, 
but in rare instances can become a panuveitis. JIA-associated 
uveitis is usually asymptomatic in the age group in which it  on
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table 3 Recommendations for treatment in juvenile idiopathic arthritis (JIA)-related uveitis
L s Agreement (%) references
9. Active uveitis in JIA usually requires immediate treatment. 2B B 100 69 71 78–80
10. Topical corticosteroids (preferably prednisolone acetate or dexamethasone) are the first-line treatment 
of anterior uveitis.
4 D 100 81
11. Topical and systemic NSAIDs have no demonstrable effect as monotherapy, but may be used as 
additional therapy.
3 C 92 79 81 82
12. Systemic immunosuppression in active uveitis is recommended if poor prognostic factors are present at 
the first visit. Poor prognostic factors including lack of remission later on during the disease course require 
systemic immunosuppression.
2A 100 4 19 22 29 55 56 65 78 83 84
13. Systemic immunosuppression is recommended if inactivity could not be reached within 3 months or 
inflammation is reactivating during steroid dose reduction.
2B B 100 55 59 68 69 78 80 85–87
14. Methotrexate is the first choice as systemic immunosuppression. 4 D 100 68 84 88–95
15. In case of methotrexate inefficacy or intolerance, adding or switching to biological treatment is 
recommended.
3 C 92 91–104
16. The use of anti-TNF treatment strategies (adalimumab>infliximab>golimumab) is recommended in 
patients with uveitis refractory/resistant to DMARD therapy, principally methotrexate.
3 C 100 86 100 101 104–117 120–124 126 127
17. Based on the current evidence, etanercept should not be considered for JIA-associated uveitis. 1B A 100 87 100 109 117–121
18. Switching between different anti-TNF treatments might be valuable if uveitis is refractory to the first 
anti-TNF, even though the present evidence comes from small case series or inception cohorts.
3 C 100 87 113 116 122
19. In case of lack of efficacy, consider testing for antidrug antibodies and drug trough level. If the patient 
has no antibodies but has low trough levels, consider increasing the dose or shortening the interval.
4 D 100
20. Tocilizumab, rituximab and abatacept might be potential options for cases refractory to previous anti-
TNF therapy.
3 C 100 123–125
Agreement indicates the % of experts that agreed on the recommendation during the final voting round of the consensus meeting.
1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 
4, expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or 
extrapolated from level 3 or 4 expert opinion.; DMARD, disease-modifying antirheumatic drugs; L, level of evidence; NSAIDs, non-steroidal anti-inflammatory drugs;  S, strength 
of evidence; TNF, tumour necrosis factor. 
table 4 Recommendations for future plans in juvenile idiopathic 
arthritis (JIA)-related uveitis
L s Agreement (%) references
21. Validated outcome measures for 
JIA-associated uveitis are needed
3 C 100 73 126–128
22. Controlled clinical trials are needed 
for JIA-associated uveitis
1B A 100 119
Agreement indicates the % of experts that agreed on the recommendation during 
the final voting round of the consensus meeting.
1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, 
cohort studies; 2B, case–control studies; 3, non-comparative descriptive studies; 
4, expert opinion (diagnostic studies); 1A, meta-analysis of randomised controlled 
trials; 1B, randomised controlled study; 2A, controlled study without randomisation; 
2B, quasi-experimental study; 3, descriptive study; 4, expert opinion (therapeutic 
studies); A, based on level 1 evidence; B, based on level 2 or extrapolated from 
level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 
or extrapolated from level 3 or 4 expert opinion. , level of evidence; S, strength of 
evidence .
most commonly develops (age 3–7 years), but severe inflamma-
tion may cause symptomatic pain and redness and these symp-
toms and signs, as well as pupil distortion, may be noticed by 
carers and lead to early referral. Reduced visual function is an 
uncommon cause of presentation in small children unless it is 
severe and usually secondary to irreversible structural damage. 
The presence of antinuclear antibodies (ANA), oligoarthritis and 
early onset of arthritis are predominant risk factors for chronic 
anterior uveitis in those with JIA, and improved identifica-
tion of children at risk is a key priority for targeted screening 
programmes. This exercise only looked at chronic anterior 
uveitis associated with JIA and not at acute anterior uveitis seen 
in human leukocyte antigen (HLA) B27-positive children with 
enthesitis-related arthritis.
Timely and aggressive treatment is clearly needed where there 
is significant damage at the time of diagnosis. However, the vari-
able course of the disease means that some significant events may 
occur years after therapy commences and there remains consid-
erable disagreement among expert practitioners about the timing 
and indications for treatment escalation.132 133
recommendations for diagnosis and screening in JIA-related 
uveitis
Screening for JIA-associated uveitis
All patients with JIA should be screened for uveitis according to 
contemporary and audited screening protocols which should be 
implemented in all centres in which patients with JIA are being 
managed.42 43 There is no necessity for the screening process to 
take place in the same institution as the rheumatological care. It 
is especially important, however, that all children in whom the 
diagnosis of JIA is being considered should have a timely check 
by a local ophthalmologist rather than wait for confirmation of 
the diagnosis from a paediatric rheumatology referral centre. It 
is the responsibility of paediatric rheumatologist to ensure chil-
dren with JIA are referred for screening. Screening starts with all 
individuals with a ‘suspected’ diagnosis of JIA and the clinical 
responsibility for organising this service needs to be clear. This 
is independent of whether it is the remit of the ophthalmolo-
gist not specialised in uveitis, paediatrician or rheumatologist 
(table 1). The evidence published to suggest that the risk factors 
originally proposed for the development of chronic uveitis in 
the JIA population (early-onset arthritis, ANA positivity and 
oligoarticular subtype) is suboptimal: the expert group noted 
that despite the fact that a number of screening protocols have 
been published there is no evidence to suggest that any one of 
them is superior.5 23 26 61 74
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Advances in genetics have not found any more specific 
diagnostic markers than the HLA types originally reported 
as being associated with both oligoarticular disease and 
uveitis.14 15 30 32 38 48 50 56 There is no evidence, at present, that 
genotyping adds specificity to the established clinical risk 
factors on which contemporary screening programmes are 
based.
Despite the advances in subtyping ANAs in other rheumatic 
disorders, there has been little advance in our understanding 
of the association of ANAs with the risk of JIA-associated 
uveitis28 34 35 41 60 67 although antibodies to nuclear structures 
such as histones and chromatin16 21 41 52–54 64 77 and ocular anti-
gens have been reported.13 33 51 75 Two studies found that chil-
dren with higher inflammatory activity (as determined by higher 
erythrocyte sedimentation rate (ESR) values) when oligoarthritis 
or polyarthritis was diagnosed had an increased risk of devel-
oping uveitis.27 31
There is a clear unmet need to adapt screening policies to the 
contemporary usage of early systemic immunosuppressant treat-
ment of arthritis57 61 62 64 and novel biomarkers and future geno-
typing may improve targeting of the population being screened.
Monitoring during follow-up
The risk of visual symptoms and potential for relapse in patients 
initially responding to treatment highlights the necessity for 
maintained regular close ophthalmological scrutiny. The expert 
group recommended that the frequency of ophthalmological 
follow-up should be based on ocular disease severity and decided 
upon in conjunction with an expert ophthalmologist.
Screening after stopping treatment of uveitis
Methotrexate (MTX) is the immunosuppressive therapy of 
choice in patients with JIA-related uveitis (see recommen-
dation 14, table 3). Once long-lasting remission of uveitis is 
achieved, MTX is usually stopped, but the optimal period of 
disease control prior to withdrawal of both topical and systemic 
treatment remains unclear. Patients stopping MTX are at risk 
of developing new onset uveitis or recurrence of uveitis after 
prolonged remission in the first year. Indeed, the majority of 
patients in a recently reported series relapsed within 24 months 
of stopping therapy.67–70 Consequently, after stopping immu-
nosuppression with MTX (prescribed for arthritis or uveitis) it 
is recommended that all patients with JIA are screened by an 
ophthalmologist at least every three months for a minimum of 
1 year.
It also remains unclear for those patients on multiple treat-
ments, in which order treatments are best withdrawn. Relapse 
of uveitis after withdrawal of MTX appears to be delayed in 
older patients, those who have been on treatment for longer 
duration.67 The authors recommended that the period of uveitis 
inactivity should be >2 years before MTX is withdrawn.67 
The expert group also recommend that patients should have 2 
years of inactive disease while not using topical steroids before 
reducing systemic immunosuppression.
There is a clear need for continuing monitoring in the early 
period of remission after medications are stopped, especially in 
patients on long-term therapy, topical or systemic, which had 
maintained disease control. The expert group recommends that 
monitoring of disease in remission by an ophthalmologist should 
be at least every three months and should continue for at least 
3 years off all forms of treatment. The length of remission best 
predicting lifetime remission remains unknown. More robust 
data on effective screening strategies are required.
recommendations for disease activity measurement in JIA-
associated uveitis
A pivotal goal in the management of JIA-associated uveitis is 
to minimise loss of vision through the early diagnosis of ocular 
morbidity. Early referral and appropriate treatment to eliminate 
ocular inflammation are seen to be crucial in preserving visual 
acuity. Visual loss is mainly caused by glaucoma, macular damage 
from inflammatory oedema, hypotony or amblyopia: structural 
damage can occur prior to diagnosis and also arise following 
years of poorly controlled inflammation.
Multiple studies have found delayed presentation with damage 
at diagnosis, surgery and length of follow-up to be the major 
risks for lifelong visual loss.4 68 78 Male gender and non-Cau-
casian race may be additional risk factors for some complica-
tions.18 19 37 56 65 71 Immunosuppressive treatment is therefore 
aimed at reducing agreed measures of active intraocular inflam-
mation which include the level of cellular infiltrate, breakdown 
of vascular barriers (eg, flare) and macular oedema: few of these 
measures have been validated and different markers may be 
appropriate in eyes with different levels of structural damage or 
at different stages of disease.134
In one study, an increase in anterior chamber cell grade was 
associated with elevated rates of visual loss in a dose-dependent 
fashion, whereas immunotherapy was associated with a reduced 
risk of visual loss, particularly for the 20/50 or worse outcome 
(HR 0.40; P<0.01).78 Others have found anterior chamber flare 
a better predictor of visual loss.63
There are no established biomarkers currently available for 
predicting disease activity or guiding treatment in JIA-associated 
uveitis and research efforts in this area need to be intensified 
(table 2).24 32 34 35 40 44 49 75–80
In a small group of children with JIA-related anterior uveitis, 
serum interleukin-2R levels were significantly increased,72 while 
in a larger cohort of children there was a significant correlation 
between the presence of anterior uveitis and aqueous humour 
levels of transthyretin.73 Until reliable biomarkers are found, 
management relies on frequent ophthalmic examination. Future 
opportunities might include gene expression and proteomic 
profiling of the serum, peripheral blood leucocytes and 
aqueous humour; measurement of acute-phase reactants; HLA 
typing and determination of ANAs.74 Evidence-based guidelines 
by the German Ophthalmological Society, the Society for Child-
hood and Adolescent Rheumatology and the German Society for 
Rheumatology noted that macular oedema, ocular hypotony and 
rubeosis iridis are often associated with chronic inflammation 
and anti-inflammatory treatment should be initiated (or intensi-
fied) even in the absence of cells in the anterior chamber.4 The 
expert group recommended that the goal of treating JIA-associ-
ated uveitis should be no cells in the anterior chamber although 
this may not be practically possible (table 2). With reference to 
the Standardization of Uveitis Nomenclature (SUN) Working 
Group, a multinational interdisciplinary group (MIWGUC) 
developed a set of core outcome measures for uveitis that may 
provide a framework for evaluating disease severity and its 
course, risk for structural impairment, levels of impairment in 
visual function and responses to treatment.74 These would be 
invaluable in clinical studies involving patients with JIA-associ-
ated uveitis. However, these proposed outcome measures remain 
to be validated in children.135 To best guide treatment decisions, 
there should be good communication between the ophthalmol-
ogist and the paediatric rheumatologist concerning changes in 
disease activity treatment changes and responsibility for treat-
ment monitoring. Recently published guidance for management 
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of non-infectious uveitis in adults has some important principles 
for the management of panuveitis in all age groups.136
recommendations for treatment in JIA-associated uveitis
Active uveitis in JIA usually requires immediate treatment. In a 
comparison of two cohorts of patients with new-onset JIA, sepa-
rated by a 10-year interval, the more recently treated patients 
received early intensive treatment and close monitoring, and 
reported fewer complications and milder uveitis with visual 
loss avoided in most cases.80 Treatment factors reported to be 
associated with improved outcomes included introduction of 
immunosuppressive therapy earlier in the course of the disease 
or at a younger age69 and treatment with immunosuppressants 
generally.71 78
Based on past usage, the expert group recommend that topical 
corticosteroids (preferably prednisolone or dexamethasone) are 
the first-line treatments of choice for both acute and chronic 
anterior uveitis.4 5 81 129 Children with JIA-related uveitis are 
frequently treated with topical corticosteroids over extended 
periods, and this increases the risk of cataract formation and 
glaucoma.
One study found that the increased risk of cataract formation 
with high-dose topical steroids was independent of active uveitis 
or presence of posterior synechiae.81 The risk increased as the 
number of drops of topical corticosteroids instilled increased. 
The data suggested that patients may be treated with low doses 
of topical corticosteroids (≤3 drops daily) over moderate periods 
of follow-up (median 4 years; range 0.5–15 years) with a low 
risk of developing cataracts.81 Among eyes receiving ≤2 drops 
daily, the incidence of cataract was 0/eye year. There appears to 
be no evidence to suggest that less potent topical steroids reduce 
adverse effects in this patient population (table 3). Systemic 
corticosteroids are not usually preferred in children due to 
risks of growth suppression and osteopenia; however, they are 
potentially helpful in individual cases for rapid control of severe 
uveitis or in the presence of macular oedema.
In a retrospective study, the adjunctive use of non-steroidal 
anti-inflammatory drugs (NSAIDs) for the treatment of chronic 
iridocyclitis was evaluated in 14 patients, 8 with JIA and 6 with 
idiopathic iridocyclitis.82 In all patients, the activity of the irido-
cyclitis improved with the addition of NSAIDs to their treatment 
regimens, permitting reduction in the dose of corticosteroid 
drugs. These data suggest that NSAID therapy may have an 
adjunctive role in the treatment of chronic iridocyclitis in child-
hood, but not as monotherapy.
Systemic immunosuppression for active uveitis is recom-
mended to reduce complications in those cases where topical 
steroids are insufficient to eliminate ocular inflammation 
short term, or such high doses are required that treatment risks 
outweigh the beneficial effects. However, the threshold for 
introducing systemic treatment is lower in those with multiple 
risks for visual loss as discussed earlier.129 Immediate systemic 
immunosuppression in active uveitis is recommended if poor 
prognostic factors are present at the first visit. Studies suggest 
instituting aggressive immunosuppression in high-risk patients 
even before there is any clear evidence of complications devel-
oping.27 39 Poor prognostic factors include uveitis antedating 
arthritis19 22 74; posterior synechia55 68 74 75; male gender19 22 55; 
band keratopathy, glaucoma and cataract55; poor initial vision, 
hypotony, macular oedema and dense vitreous body opacifica-
tion55; and lack of remission later on during the disease course 
(table 3). Age at the time of uveitis onset does not appear to be 
a risk factor.22 56
definition of treatment failure
Treatment failure should lead to a change in treatment dose, 
route or modality taking into consideration the fact that many of 
the drugs require different times to achieve their optimal effect 
and there are sometimes only a limited number of drugs avail-
able. Inappropriate drug changes may result from difficulties in 
achieving consensus on the definition of treatment failure. In 
a retrospective study, the clinical outcome of 23 patients with 
JIA-associated uveitis unresponsive to corticosteroids was ascer-
tained. Uveitis was controlled using immunosuppressive therapy 
in all cases.86 Patients treated within 4–30 months from onset 
of uveitis achieved better improvement of vision compared 
with patients who received immunosuppressive therapy after 3 
years (P<0.005 for right and left eyes pooled; P=0.0075 for 
best eyes; P=0.0375 for worst eyes). These data are supported 
by findings from the SITE study which reported that among 
patients with JIA-associated uveitis receiving tertiary care use 
of immunosuppressants reduced the risk of vision loss by about 
60%.78 The expert group recommended that systemic immuno-
suppression should be used if inactivity cannot be achieved with 
topical steroids within 3 months or inflammation is reactivated 
during steroid dose reduction. The benefits of immunosuppres-
sive therapy are now well recognised, and, in general, patients in 
remission received this treatment earlier in the course of disease 
compared with patients who relapsed.55 59 68 78–87
Based on findings of efficacy and tolerability/safety from a 
number of studies, the expert group recommended that MTX 
is the immunosuppressive therapy of choice in patients with 
JIA-related uveitis.68 84 88–90 Other forms of immunosuppres-
sive therapy such as azathioprine, sulfasalazine, mycopheno-
late mofetil, cyclosporine and leflunomide have been assessed 
in patients with uveitis, often in MTX-resistant cases.91 95 The 
studies have generally included a small numbers of patients, and 
in the case of cyclosporine, the clinical efficacy was poor and the 
authors noted that it has limited value in this indication.94 The 
results with other forms of immunosuppressive therapy were 
more encouraging, but were in fewer patients.91–93 95 At this 
stage they may prove to be useful treatment options in patients 
not responding to, or who cannot tolerate, MTX and they also 
have a place accompanying biological treatment in those who 
are MTX-intolerant. There is also evidence of the greater effec-
tiveness of MTX in controlling arthritis in JIA compared with 
other conventional immunosuppressants. It is not uncommon 
for treatment to fail when treatments other than MTX are used 
because of recurrent arthritis rather than failure to control the 
uveitis.
As noted above, the evidence with other forms of immu-
nosuppressive therapy in patients with JIA-related uveitis is 
low,91–95 whereas many conventional immunosuppressants are 
used in adult onset uveitis with no specific agent favoured as 
the first choice. In both adult and childhood patients who fail 
to respond to conventional immunosuppressants, expert groups 
recommend adding or switching to biological treatments. There 
is a growing number of studies supporting the use of biological 
therapy in MTX refractory uveitis.93–108 A wide range of biolog-
ical therapies have been investigated in JIA-related uveitis refrac-
tory to conventional therapy, with adalimumab being the most 
widely studied; other agents investigated include infliximab, 
daclizumab, etanercept, golimumab, abatacept, tocilizumab and 
rituximab.96–108 123–125
All of the biological therapies investigated produced some 
benefit in patients with uveitis refractory to conventional 
therapy.86 100–127 There are very few comparative studies. One 
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table 5 Proposed domains and items for outcome measures of juvenile idiopathic arthritis (JIA)-associated uveitis (from the Multinational 
Working Group in JIA-related uveitis)74
domains Items
Grade of cells in anterior chamber Slit-lamp examination (according to SUN criteria)
Grade of flare in anterior chamber* Slit-lamp examination for routine clinical practice and prospective trials (according to SUN criteria)
Laser flare photometry for prospective trials
Number of visits with active uveitis Records of treating physician
 ► Duration of activity over a minimum of four visits/year
Visual acuity (appropriate test for age) Best-corrected visual acuity
Thresholds: ≤20/50, ≤20/200 and no light perception
Estimate contribution of amblyopia, yes/no
Development of structural complications Synechiae, yes/no
 ► Initial and additional
Ocular hypotony, yes/no (<5 mm Hg)
Ocular hypertension, yes/no (>21 mm Hg)
Glaucoma, yes/no
Cataract, yes/no
Band keratopathy in the central cornea, yes/no
Macular oedema by optical coherence tomography, yes/no
 ► Funduscopy and optical coherence tomography for routine clinical practice (for macula and optic disc)
 ► Funduscopy and optical coherence tomography for prospective trials
Epiretinal membrane formation, yes/no
 ► Funduscopy for routine clinical practice
 ► Funduscopy and optical coherence tomography for prospective trials
Quality of life Childhood Health Assessment Questionnaire
Child Health Questionnaire
Pediatric Quality of Life Inventory
Uveitis-specific quality of life instrument (not yet available for non-English speaking countries)
Overall uveitis-related disability Assessment by parents, visual analogue scale
Assessment by children, visual analogue scale
Assessment by treating ophthalmologist, visual analogue scale
Assessment by treating paediatric rheumatologist, visual analogue scale
Social outcome School/kindergarten absence
Anti-inflammatory medication* Reduction of corticosteroid dose—topical dose—systemic dose
Surgery* Yes/no
Biomarkers Research tools (not currently available
*Not an outcome measure, but should be documented.
SUN, Standardization of Uveitis Nomenclature.
study found infliximab to be significantly superior to etanercept 
in children with refractory JIA-associated chronic uveitis.100 
In another small study, adalimumab was more efficacious than 
infliximab when used as first-line anti-TNF treatment.106 Adali-
mumab also produced higher remission rates versus infliximab in 
the medium-term treatment (at least 12 months) of patients with 
JIA-related uveitis107 and in children with uveitis it was signifi-
cantly superior to infliximab in maintaining remission over a 
3-year treatment period.102 The expert group recommends treat-
ment with anti-tumour necrosis factor (TNF) agents (adalimum-
ab>infliximab>golimumab) in patients with uveitis refractory/
resistant to disease-modifying antirheumatic drug (DMARD) 
therapy, principally methotrexate.86 100–127
The use of TNF inhibitors in uveitis was hypothesised based on 
their proven efficacy in a range of systemic inflammatory disor-
ders including JIA, rheumatoid arthritis and Crohn’s disease.109 
Etanercept is a recombinant DNA dimeric fusion protein that 
antagonises TNF-α, and it has proven to be effective in chil-
dren with polyarticular JIA.118 Evidence for the clinical benefit 
of etanercept in uveitis has generally been disappointing; it was 
associated with a high relapse rate and a high risk for developing 
uveitis flares.87 100 109 117–121 Based on these findings, the expert 
group recommend that etanercept should not be considered for 
JIA-associated uveitis.
Findings from studies including small numbers of patients 
provide evidence that if treatment with one anti-TNF agent 
becomes ineffective switching to a different anti-TNF agent 
could prove to be clinically beneficial.87 113 116 122 The efficacy 
and safety of adalimumab was evaluated in in 26 children with 
JIA resistant to current therapy (disease-modifying drugs in 17 
cases and anti-TNF agents in 9 cases). Switching to adalimumab 
had a beneficial impact on disease control in 17 (65.4%) of 
patients.113 In total, 17 patients with severe recalcitrant uveitis 
(resistant to etanercept, infliximab, adalimumab, rituximab or 
abatacept) were switched to golimumab and 14 achieved a posi-
tive response, and in 12 of these the disease was inactive at the 
final visit (mean duration 22 months; range 6–29 months).116 
Dhingra et al reported preliminary evidence that in seven 
cases of refractory uveitis switching between biological agents 
(over a period of 5–24 months) helped to control intraocular 
inflammation.122
While the literature search revealed no direct evidence of the 
effects of low drug trough levels or the development of anti-drug 
antibodies (ADAs) on the clinical efficacy of biological agents in 
patients with uveitis, the expert group considered findings from 
other clinical settings. They concluded that in cases of loss of 
efficacy over time consideration should be given to testing for 
ADAs and drug trough levels.137 138 If the patient has no anti-
bodies, but has low trough levels, increasing the dose or short-
ening the interval may be an option.139
In keeping with an earlier recommendation (18, table 3), there 
are data from small studies that in patients with JIA-related uveitis 
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refractory to conventional therapy and at least one anti-TNF 
therapy switching to drugs such as abatacept, rituximab or tocili-
zumab may be beneficial.123–125 This included patients in whom 
the main cause of poor visual acuity was macular oedema.125 
There is now growing evidence for the role of tocilizumab in 
macular oedema associated with uveitis.140 141 There is also an 
ongoing trial of tocilizumab in children with anti-TNF refractory 
JIA-associated uveitis (http://www. aptitude- trial. org. uk/).
The optimum time for surgery in children with complica-
tions from refractory uveitis has not been addressed as a recom-
mendation due to paucity of evidence. Recent literature does 
demonstrate that a significant number of children with uveitis 
still require surgery for complications.142
recommendations for future plans in JIA-related uveitis
A MIWGUC identified the need for clinical trials and longitu-
dinal studies to determine the benefits and costs of health inter-
ventions in this setting.74 To achieve this the group proposed 
a core set of outcomes aimed at ensuring that changes in rele-
vant outcomes were measured, and that standardisation of 
outcome measures would facilitate data pooling and compar-
isons between interventions (tables 4 and 5). The outcomes 
should be agreed on by both researchers and patients, and 
they will provide a common focus for interventional studies. 
Disease-specific and universally agreed on validated outcomes 
are likely to reduce selective reporting and reporting bias.74 
A limitation of this core set of outcomes is that, despite the 
fact that there was consensus by the Working Group regarding 
their utility, they still remain unvalidated. Visual impairment 
has a significant impact on the quality of life (QOL) of patients 
with JIA-related uveitis and vision-related QOL relates to 
the degree to which vision impacts the individual’s ability to 
perform activities of daily living as well as social, emotional 
and economic well-being.126–128 The Effects of Youngsters’ 
Eyesight QOL is a useful instrument for measuring the effects 
of uveitis on QOL which is currently being validated.
The expert group indicated a need for more well-controlled 
clinical trials in children with JIA-related uveitis to provide 
the scientific best evidence in the areas of diagnosis, screening, 
disease activity and treatment to enable the optimal care of these 
patients.
dIsCussIOn
Following a systematic review of the literature and Nominal 
Group Technique methodology, under the auspices of SHARE 
and EULAR operating procedures, 22 recommendations for 
the screening, diagnosis, disease activity monitoring, treatment 
and future plans for children with JIA-associated uveitis were 
accepted with at least 80% agreement. In a disease setting where 
the evidence base is limited by small numbers of patients, and 
which is developing rapidly, these expert recommendations 
should help specialists with the evidence-based advice to provide 
optimal care for their patients.
It should be noted that, in general, the level of evidence 
was quite low with 13 of 22 recommendations being level 3 
or 4, seven level 2 and only two level 1. This highlights the 
need for more research in this clinical setting where a number 
of new therapies, particularly biological agents, have been 
introduced in recent years. At the time that the data search 
for this article took place, the expert group noted a need for 
more well-controlled clinical trials in children with JIA-related 
uveitis. The goal being to ensure that scientific best evidence is 
used to support optimal treatment. In the interim period, but 
clearly outside the search time frame of this review, a well-de-
signed randomised controlled trial (RCT) has been published 
which compared adalimumab with placebo in children with 
JIA-related uveitis who were taking a stable dose of MTX.135 
Active treatment was shown to control inflammation and was 
associated with a lower rate of treatment failure compared 
with placebo. These results do not alter the recommendations 
of the expert group, but reinforce the intent of recommen-
dation 15 in table 3: ‘In case of methotrexate inefficacy or 
intolerance, adding or switching to biological treatment is 
recommended’. The only difference being that this recommen-
dation is now supported by level 1 evidence, rather than level 
3 evidence. More recently, another smaller RCT of adalim-
umab has also been published showing efficacy of adalimumab 
in JIA–uveitis although this study used flare as the primary 
outcome measure.143 The utility of biological therapies is 
receiving wider attention, for example, a number of studies 
have reported the benefits of tocilizumab.141 144 These findings 
from outside the systematic data search time period empha-
sise the need to regularly update the recommendations of the 
JIA-associated uveitis expert group so as to provide the highest 
levels of care in this clinical setting.
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